Liquid Biopsy with Emphasis on NIPT: Global Markets to 2023

Summary Table: Global Liquid Biopsy Market, by Disease Class, Through 2023
Table 1: Liquid Biopsy Sample Types
Table 2: Liquid Biopsy Biomarker Classes
Table 3: Clinical Implications of CTCs
Table 4: Key Applications of Circulating Tumor DNA (ctDNA)
Table 5: Comparison between Applications of ctDNA, CTCs and Exosomes
Table 6: Single-Cell Analysis to Identify Cancer Driver Mutations
Table 7: Genomics-Based Oncology Workflow
Table 8: Unique Challenges of CTC Capture and Analysis
Table 9: CTC Workflow
Table 10: Cell Differentiators
Table 11: Cell Isolation Technologies
Table 12: CTC-Isolating Markers
Table 13: CTC Sample Preparation Technologies
Table 14: Single-Cell Analysis Technologies
Table 15: Difference between Liquid Biopsy and Traditional Biopsy
Table 16: Estimated Annual Solid Biopsy Procedures Performed in the U.S. for Selected Cancers
Table 17: Main Risks for Needle-Based Tissue Biopsies
Table 18: Factors in Tissue Biopsy
Table 19: Prenatal Invasive Testing Technologies
Table 20: Invasive versus Noninvasive Prenatal Technologies
Table 21: Growth Driving Forces
Table 22: Key Trends in Liquid Biopsy Market
Table 23: Key Liquid Biopsy Research and Development Programs
Table 24: Source of Foreign Biomarkers for Liquid Biopsy Applications
Table 25: Personalized Medicine Driven by Cancer Common Genetic Mutations
Table 26: Cancer Liquid Biopsy Biomarker Clinical Status
Table 27: Cancer Liquid Biopsy Market Segments
Table 28: Reproductive Health Screening Application
Table 29: Ethical Issues Associated with NIPT
Table 30: Transplant Diagnostics Application
Table 31: Key Segments within the Liquid Biopsy Industry
Table 32: Advanced Sequencing Industry Company Positioning
Table 33: End-to-End Sequencing Approaches
Table 34: Next-Generation Sequencing Instrument Companies
Table 35: NGS Instruments
Table 36: Benchtop and Handheld Sequencer Platforms
Table 37: 3GS Industry, by Tier Status
Table 38: Advantages of Droplet Digital PCR for Single-Cell Analysis
Table 39: Droplet Digital PCR Industry
Table 40: Target Enrichment Industry
Table 41: Single-Cell DNA Polymerase Industry
Table 42: Next-Generation Sequencing Clinical Informatics Company Positioning
Table 43: Selected NGS Clinical Testing Laboratories
Table 44: NIPT Industry
Table 45: Estimated Market Share for NIPT, 2018
Table 46: German NGS-Based Noninvasive Prenatal Diagnostic Companies, 2017
Table 47: NIPT Test Licensing, by Country
Table 48: Fetal Cell NIPT Industry
Table 49: CTC Capture and Detection Industry
Table 50: Liquid Biopsy Industry by Company Focus
Table 51: Example of NGS-Based Liquid Biopsy Market Differentiation
Table 52: Key Competitors in the Direct-to-Consumer Genetic Testing Industry
Table 53: Liquid Biopsy Key Growth Driving Forces
Table 54: Global Liquid Biopsy Market, by Application, Through 2023
Table 55: Global Liquid Biopsy Market, by Biomarker Type, Through 2023
Table 56: FDA-Approved or CE-Marked Tests with Epigenetic Component
Table 57: Global Liquid Biopsy Market, by Analysis Platform, Through 2023
Table 58: Global Liquid Biopsy Market, by Analysis Purpose, Through 2023
Table 59: Global Liquid Biopsy Market, by Region, Through 2023
Table 60: Limitations of Solid Biopsy in Cancer Applications
Table 61: Low-Frequency Mutation Detection
Table 62: Global Liquid Biopsy Cancer Market, by Indication, Through 2023
Table 63: Five-Year Survival Rate for Ovarian Cancer
Table 64: National Institutes of Health Liquid Biopsy Early Detection Initiative
Table 65: Molecular Thyroid Nodule Classifier Test Company Positioning
Table 66: Global Liquid Biopsy Cancer Market, by Analysis Purpose, Through 2023
Table 67: MRI and Liquid Biopsy Methods
Table 68: Early Detection Tissue of Origin Approaches
Table 69: Global Liquid Biopsy Cancer Market, by Biomarker Class, Through 2023
Table 70: Global Liquid Biopsy Cancer Market, by Analysis Method, Through 2023
Table 71: Global Breast Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
Table 72: Global Colorectal Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
Table 73: Global Hematological Cancer Market, by Analysis Method, Through 2023
Table 74: Global Lung Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
Table 75: Global Pan-Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
Table 76: Global Cancer Liquid Biopsy Market, by Region, Through 2023
Table 77: Global Liquid Biopsy Transplant Market, by Analysis Purpose, Through 2023
Table 78: Global Liquid Biopsy Transplant Market, by Organ Type, Through 2023
Table 79: Transplant Procedures Performed in the U.S., 2016-Sept. 30, 2018
Table 80: Global Liquid Biopsy Transplant Market, by Analysis Method, Through 2023
Table 81: Global Liquid Biopsy Transplant Market, by Biomarker Class, Through 2023
Table 82: Global Transplant Liquid Biopsy Market, by Region, Through 2023
Table 83: NIPT Test Prices Across the Globe, 2017
Table 84: Global NIPT Market, by Analysis Purpose, Through 2023
Table 85: Global NIPT Market, by Risk Type, Through 2023
Table 86: Global NIPT Market, by Biomarker Class, Through 2023
Table 87: Global NIPT Market, by Analysis Method, Through 2023
Table 88: NGS NIPT Industry
Table 89: Number of Tests and Market for NIPT, by Region and Company, 2015
Table 90: Germany NGS-Based Noninvasive Prenatal Diagnostic Companies
Table 91: Global NIPT Market, by Method, Through 2023
Table 92: NIPTs Offered by Various Companies
Table 93: Positive Predictive Values for High- and Average-Risk Cohorts
Table 94: Comparison with Other NIPTs That are Based on Counting Technologies
Table 95: Global Iona Test Market, by Country/Region, 2016 and 2017
Table 96: informaSeq Tests
Table 97: informaSeq Test Performance in the Most Common Chromosomal Aneuploidies
Table 98: informaSeq Test Performance in the Most Common Sex Chromosomes
Table 99: VisibiliT Test Performance
Table 100: Global NIPT Market, by Region, Through 2023
Table 101: North American NIPT Market, by Country, Through 2023
Table 102: Commercial Landscape of Noninvasive Prenatal Testing for Fetal Aneuploidy in the U.S.
Table 103: U.S. Patents and Applications for Institutions Commercializing Noninvasive Prenatal Tests, 2012
Table 104: European NIPT Market, by Country, Through 2023
Table 105: Asia-Pacific NIPT Market, by Country, Through 2023
Table 106: NIPT Technology Transfers, by Country
Table 107: Patent Review of NIPT, by Year, 2010-2018
Table 108: CTC-Related Patents, by Region, 2007-2019*
Table 109: Cell-Free DNA-Related Patents, by Region, 2007-2017
Table 110: Status of Liquid Biopsy- and Sequencing-Related Patent Disputes
Table 111: Mergers and Acquisitions of Key Players, 2016-2018
Table 112: New Products Launched by Key Players of NGS-NIPT Industry, 2017 and 2018
Table 113: Agreements, Collaborations and Partnerships among Liquid Biopsy-NIPT Key Players, 2017 and 2018
Table 114: Pipeline Analysis of Liquid Biopsy Industry, 2017 and 2018
Table 115: 10x Genomics: Products and Services
Table 116: Agilent Technologies: Financials, 2016-2017
Table 117: Agilent Technologies: Products and Services
Table 118: Berry Genomics: Products and Services
Table 119: BGI: Products and Services
Table 120: LifeCodexx: Products and Services
Table 121: Illumina: Financials, 2016-2017
Table 122: Illumina: Products and Services
Table 123: LabCorp: Financials, 2016-2017
Table 124: LabCorp: Products and Services
Table 125: Natera: Financials, 2016-2017
Table 126: Natera: Products and Services
Table 127: Oxford Nanopore Technologies: Products and Services
Table 128: Pacific Biosciences: Financials, 2016-2017
Table 129: PacBio: Products and Services
Table 130: PDx: Products and Services
Table 131: QIAGEN: Financials, 2016-2017
Table 132: QIAGEN: Products and Services
Table 133: Roche Diagnostics: Division Sales, 2016-2017
Table 134: Roche Diagnostics: Products and Services
Table 135: Thermo Fisher: Financials, 2016-2017
Table 136: Thermo Fisher: Products and Services

Summary Figure: Global Liquid Biopsy Market, by Disease Class, 2017-2023
Figure 1: Timeline of Liquid Biopsy Development
Figure 2: Molecular Applications of Biomarkers as Liquid Biopsy for Personalized Medicine
Figure 3: How Cancer Genomics Drives Liquid Biopsy
Figure 4: Clinical Applications of Liquid Biopsy for Precision Medicine
Figure 5: NIPT Using Massively Parallel Sequencing (MPS)
Figure 6: Global NIPT Market, by Risk Type, 2017-2023
Figure 7: Clinical Performance of NIFTY Test
Figure 8: Clinical Performance of Harmony Test
Figure 9: Clinical Performance of Panorama Test
Figure 10: North American NIPT Market, 2017-2023
Figure 11: European NIPT Market, 2017-2023
Figure 12: European NIPT Market Share, 2017
Figure 13: Mean Maternal Age in Five EU Countries, 2016
Figure 14: Total Number of Pregnancies and NIPT Procedures in Five EU Countries, 2016
Figure 15: Asia-Pacific NIPT Market, 2017-2023
Figure 16: RoW NIPT Market, 2017-2023
Figure 17: Prevalence of Down Syndrome by Mother's Age
Figure 18: Global NIPT Market Share, by Key Players, 2018
Figure 19: Thermo Fisher Scientific: Market Share, by Business Segments, 2018 (Q1)